Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Placebo Matching Mitapivat
Agios Netherlands B.V.
Non-Transfusion-dependent Alpha-Thalassemia
1 trial -
Placebo Nasal Aerosol
Teva Pharma GmbH
Perennial Allergic Rhinitis
1 trial -
Placebo Ocrelizumab, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg
Hoffmann-La Roche
Primary Progressive Multiple Sclerosis (PPMS)
1 trial -
Placebo Ocrevus, DIPHENHYDRAMINE HYDROCHLORIDE, METHYLPREDNISOLONE , METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Ocrevus 300 mg concentrate for solution for infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Dormutil N, Ocrevus 300 mg concentrate for solution for infusion
Hoffmann-La Roche
Primary progressive multiple sclerosis (PPMS)
1 trial -
Placebo Rosuvastatin Calcium 20 mg tablets, ROSUVASTATIN CALCIUM
The George Institute
Venous thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis
1 trial -
Placebo Spiromax
Teva Pharma GmbH
Asthma
1 trial -
Placebo Trontinemab, Amyvid 800 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, Trontinemab, [18F]MK-6240
Hoffmann-La Roche
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
1 trial -
Placebo cannabis oil. Components: cannabis granulated flos after (ethanol) extraction of cannabinoids; arachidis oleum raffinatum., TA-CBD 10
Disc Medicine
Refractory Epilepsy
1 trial -
Placebo capsules for Doxycycline 200 mg (Empty Hpmc capsule, vcaps plus, swedish orange filled with microcrystalline cellulose), Doxycycline EG 100 mg tabletten
The George Institute
bacterial sexually transmitted infections
1 trial -
Placebo contains excipients only and is visually indistinguishable from the Telitacicept, Telitacicept injection
Vor Biopharma
Generalized Myasthenia Gravis
1 trial -
Placebo de PREDNISONE ARROW 20 mg, PREDNISONE ARROW 20 mg, comprimé sécable
Pari Pharma GmbH
Septic arthritis
1 trial -
Placebo de fasturtec, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.
Pari Pharma GmbH
Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level ≥200µmol/L, adults, negative G6PD deficiency
1 trial -
Placebo de formule développée spécifiquement pour la recherche par la PUI (cf IMPD-Q), CLOBETASOL PROPIONATE
Pari Pharma GmbH
Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.
1 trial -
Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota
Pari Pharma GmbH
Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery
1 trial -
Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota
Pari Pharma GmbH
Patients colonized with MDR-GNB
1 trial -
Placebo du FORXIGA 10 mg, Forxiga 10 mg film-coated tablets
Pari Pharma GmbH
Adult patients discharged alive from ICU with a decreased eGFR, and/or an AKI during ICU stay and/or an elevated NT-proBNP at discharge.
1 trial -
Placebo efgartigimod IV concentrate for solution, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion
argenx
Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
1 trial -
Placebo for AMG 145, EVOLOCUMAB
Amgen
Adults at high risk of cardiovascular events without prior MI or stroke.
1 trial -
Placebo for AMG 334, Erenumab
Amgen
Chronic Migraine
1 trial -
Placebo for AMG 890
Amgen
Cardiovascular Disease
1 trial -
Placebo for ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion
Lacuna Pharma Pty Ltd
complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)
1 trial -
Placebo for AZP-3601 Pen A and Pen B, AZP-3601, CALCIUM ARROW 500 mg, comprimé à sucer, AZP-3601, UN-ALFA 0,50 microgramme, capsule molle, ROCALTROL 0,25 microgramme, capsule molle
Alexion Europe SAS
Hypoparathyroidism
1 trial -
Placebo for Acetylsalicylic Acid, ACETYLSALICYLIC ACID, REGN7508, Placebo for REGN7508
Lacuna Pharma Pty Ltd
Symptomatic Venous Thromboembolism (VTE)
1 trial -
Placebo for Adalimumab
AbbVie
Rheumatoid Arthritis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources